Cargando…
A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma
In 2021, pancreatic ductal adenocarcinoma (PDAC) is the 3(rd) leading cause of cancer deaths in the United States. This is largely due to a lack of symptoms and limited treatment options, which extend survival by only a few weeks. There is thus an urgent need to develop new therapies effective again...
Autores principales: | Lewis, Clayton S., Karve, Aniruddha, Matiash, Kateryna, Stone, Timothy, Li, Jingxing, Wang, Jordon K., Versteeg, Henri H., Aronow, Bruce J., Ahmad, Syed A., Desai, Pankaj B., Bogdanov, Vladimir Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358774/ https://www.ncbi.nlm.nih.gov/pubmed/34395257 http://dx.doi.org/10.3389/fonc.2021.691685 |
Ejemplares similares
-
Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update
por: Matiash, Kateryna, et al.
Publicado: (2021) -
Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma
por: Unruh, Dusten, et al.
Publicado: (2016) -
A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma
por: Luo, Wen, et al.
Publicado: (2023) -
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
por: Mishra, Rosalin, et al.
Publicado: (2021) -
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021)